Pazonat 400mg Tablets Pazonat 400 contains Pazopanib, a potent oral multi-targeted receptor tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR-1, -2, and -3), platelet-derived growth factor receptors (PDGFR-α and -β), and stem cell factor receptor (c-KIT). By inhibiting intracellular autophosphorylation of these receptors, Pazopanib blocks downstream signaling pathways necessary for tumor angiogenesis, vascular permeability, endothelial cell migration, and tumor cell growth. Pazonat* 400 is indicated for the treatment of advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma (STS) in patients who have received prior chemotherapy.